NASDAQ$BCAB
Bioatla Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Announced financial results for the first quarter ended March 31, 2023, and provided highlights on its clinical programs.
BioAtla reported a net loss of $27.5 million for the first quarter ended March 31, 2023, compared to a net loss of $24.3 million for the same quarter in 2022. The company's cash and cash equivalents were $192.7 million as of March 31, 2023, which is expected to fund planned operations into 2025.
- Advanced CAB-AXL BA3011 in ongoing sarcoma Phase 2 studies, including a potentially registrational study in Undifferentiated Pleomorphic Sarcoma (UPS).
- On track for submitting a meeting request to the FDA for the potentially registrational BA3011 Phase 2, part 2 non-small cell lung cancer (NSCLC) study in 1H23.
- Enrolling BA3021 Phase 2 NSCLC study including more frequent, dose-intensive regimen.
- Cash balance of $192.7 million expected to provide funding into 2025.
Headline financials
Revenue & EPS history
Bioatla · Revenue · Quarterly
$0
Forward guidance
BioAtla anticipates several milestones, including FDA feedback for BA3011 in NSCLC, interim readout for BA3021 in NSCLC, and Phase 1 data readout for CAB-CTLA-4.
Tailwinds
- Initiation of Phase 2, part 2 potentially registrational BA3011 trial in NSCLC following anticipated FDA feedback.
- Phase 2 interim readout for BA3021 in NSCLC.
- Phase 1 data readout for our CAB-CTLA-4 basket trial.
- Initiation of Phase 2 BA3071 trial in multiple indications.
- Opening centers for our first CAB bispecific antibody, BA3182 for the potential treatment of adenocarcinomas.
Headwinds
- Potential delays in clinical and pre-clinical trials due to the global COVID-19 pandemic.
- Delays in regulatory review.
- Manufacturing and supply chain interruptions.
- Adverse effects on healthcare systems.
- Disruption of the global economy.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q1 2023
+5.5%
Avg return
Earnings day
+4.7%
Avg return
5 days after
+7.5%
Avg return
30 days after
48%
10 / 21 earnings
Positive
+76.7%
Q2 2022
Best reaction
-37.3%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.4% | -18.1% | -15.1% | |
| Q3 2025 | +23.2% | +75.8% | +24.8% | |
| Q2 2025 | -5.6% | +3.2% | +41.3% | |
| Q1 2025 | -7.2% | -9.1% | +1.5% | |
| Q4 2024 | -4.9% | -13.5% | +12.2% | |
| Q3 2024 | +1.9% | +6.3% | -20.4% | |
| Q2 2024 | +5.8% | +0.7% | +25.2% | |
| Q1 2024 | +13.6% | +7.2% | -40.5% | |
| Q4 2023 | +48.5% | +47.6% | -3.4% | |
| Q3 2023 | -10.3% | -24.2% | -15.8% | |
| Q2 2023 | -0.3% | -8.4% | -16.1% | |
| Q1 2023 | +10.9% | +7.9% | +10.3% | |
| Q4 2022 | +0.9% | +0.4% | +48.3% | |
| Q3 2022 | +17.1% | +22.8% | +63.1% | |
| Q2 2022 | +76.7% | +86.9% | +142.2% | |
| Q1 2022 | -37.3% | -43.9% | -28.2% | |
| Q4 2021 | +1.9% | -15.1% | -22.8% | |
| Q3 2021 | -0.3% | -1.9% | -24.5% | |
| Q2 2021 | -4.4% | -2.7% | -9.4% | |
| Q1 2021 | -2.4% | -1.9% | +6.6% | |
| Q4 2020 | -10.6% | -21.5% | -21.4% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro